Adapting Neurological Care Amid COVID-19

As the ongoing battle against the spread of COVID-19 continues, the medical community is learning more about the disease and at-risk populations by the day. Many symptoms and comorbidities associated with neurologic disorders place patients, especially those in the neuromuscular disease community, within those high-risk categories established by the Centers for Disease Control and Prevention (CDC).

To learn more about what health care providers for patients with conditions like spinal muscular atrophy, Duchenne muscular dystrophy, and amyotrophic lateral sclerosis, among others, are doing in response to COVID-19, NeurologyLive connected with Barry J. Byrne, MD, Ph.D., chief medical adviser to the Muscular Dystrophy Association (MDA) and associate chair of pediatrics and director at the University of Florida’s Powell Center for Rare Disease Research and Therapy. Byrne discussed the MDA’s resource center, advice that has been shared with patients and care centers, and those in this community who are at particular risk.

Learn more about Adapting Neurological Care Amid COVID-19.